Annual Report

The report describes revenue of BDT 10,217.93 million and 43 new products introduced in 2013-14. It reports that operations began at new pharmaceutical facilities, including Cephalosporin and BFS facilities. Its CSR activities included medicinal-plant farming with rural communities, training and capacity building, education support, and free medicines and health camps.